Cover image for Vol. 121 Issue 11

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians


  1. 1 - 100
  2. 101 - 136
  1. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program

      Han-Mo Chiu, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Yi-Chia Lee, Shin-Liang Pan, Ming-Shiang Wu, Chao-Sheng Liao, Hsiu-Hsi Chen, Shin-Lan Koong and Shu-Ti Chiou

      Article first published online: 20 MAY 2015 | DOI: 10.1002/cncr.29462

      A significant reduction in colorectal cancer mortality resulting from fecal immunochemical testing is demonstrated by a large, population-based, nationwide service screening program with a maximum follow-up of 6 years. Although long-term follow-up of this nationwide service screening program is required, these findings are useful for convincing health decision makers that the continuous promotion of such a nationwide screening program is worthwhile.

  2. Editorial

    1. Where does it FIT?: The roles of fecal testing and colonoscopy in colorectal cancer screening

      Grace Clarke Hillyer and Alfred I. Neugut

      Article first published online: 20 MAY 2015 | DOI: 10.1002/cncr.29459

      Although colonoscopy is predominant among the selection of colorectal cancer screening tests, stool testing (particularly fecal immunochemical testing) has also carved out an important niche for itself. Its simplicity and low cost make it ideal for mass population screening both in the United States and abroad, and it is an alternative choice for those reluctant to undergo endoscopy.

  3. Correspondence

  4. Original Articles

    1. Discipline

      Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007

      Sheila Weinmann, Andrew E. Williams, Aruna Kamineni, Diana S.M. Buist, Erin E. Masterson, Natasha K. Stout, Azadeh Stark, Tyler R. Ross, Christopher L. Owens, Terry S. Field and Chyke A. Doubeni

      Article first published online: 18 MAY 2015 | DOI: 10.1002/cncr.29445

      Over a 10-year period, with the adoption of new guidelines, Papanicolaou testing appears to have decreased, whereas human papillomavirus testing rates and the interval between Papanicolaou tests increased. The results of the current study suggest that these changes in cervical screening practices did not change the rates of detection of clinically significant lesions.

    2. Complementary Medicine
      A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus–induced prostate-specific antigen responses

      Przemyslaw Twardowski, Noriko Kanaya, Paul Frankel, Timothy Synold, Christopher Ruel, Sumanta K. Pal, Maribel Junqueira, Manisha Prajapati, Tina Moore, Pamela Tryon and Shiuan Chen

      Article first published online: 18 MAY 2015 | DOI: 10.1002/cncr.29421

      Therapy with white button mushroom (Agaricus bisporus) powder decreases prostate-specific antigen (PSA) levels in biochemically recurrent prostate cancer patients. In some cases, it also produces durable, complete PSA responses. Correlative analyses of both cytokines and myeloid-derived suppressor cells reveal significantly higher baseline levels of interleukin-15 and a decrease in the percentage of myeloid-derived suppressor cells after treatment in patients who have experienced PSA complete response.

    3. Disease Site

      Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme

      Young-Hoon Kim, Tackeun Kim, Jin-Deok Joo, Jung Ho Han, Yu Jung Kim, In Ah Kim, Chang-Ho Yun and Chae-Yong Kim

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29439

      Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy. A prospective randomized study may be indicated.

    4. Discipline

      Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer

      Manasi S. Shah, David R. Fogelman, Kanwal Pratap Singh Raghav, John V. Heymach, Hai T. Tran, Zhi-Qin Jiang, Scott Kopetz and Carrie R. Daniel

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29440

      The joint contribution of chronic systemic inflammation and obesity to the survival of patients with metastatic colorectal cancer has not been reported previously. Although no association is observed for body mass index alone in the current study, obese patients with high serum marker levels at baseline experienced the highest risk of death in this cohort.

    5. Disease Site

      Genitourinary Disease
      Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

      Jie-Fu Chen, Hao Ho, Jake Lichterman, Yi-Tsung Lu, Yang Zhang, Mitch A. Garcia, Shang-Fu Chen, An-Jou Liang, Elisabeth Hodara, Haiyen E. Zhau, Shuang Hou, Rafi S. Ahmed, Daniel J. Luthringer, Jiaoti Huang, Ker-Chau Li, Leland W. K. Chung, Zunfu Ke, Hsian-Rong Tseng and Edwin M. Posadas

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29455

      In this observational study, the authors use NanoVelcro chips to isolate circulating tumor cells (CTCs) from patients with prostate cancer and generate cell images appropriate for histopathological analysis and nuclear size measurement. In doing so, the authors identify a CTC subset of very small nuclear CTCs that exhibits significant correlation with the presence of visceral metastases and can be explored as a potential biomarker for this lethal progression in patients with prostate cancer.

  5. Editorial

    1. Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

      Sumanta K. Pal, Neeraj Agarwal and Jeremy O. Jones

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29454

      The enumeration of circulating tumor cells has established prognostic value in patients with metastatic castration-resistant prostate cancer. Herein, the authors comment on a study examining the usefulness of evaluating the nuclear size of circulating tumor cells across various stages of prostate cancer.

  6. Original Articles

    1. Discipline

      Psychosocial Oncology
      Male-female patient differences in the association between end-of-life discussions and receipt of intensive care near death

      Rashmi K. Sharma, Holly G. Prigerson, Frank J. Penedo and Paul K. Maciejewski

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29417

      End-of-life discussions dramatically decrease the likelihood of intensive care unit care near death for male patients but not for female patients. Efforts to promote end-of-life discussions between male patients and their oncologists are indicated.

    2. Clinical Trials
      The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: A randomized controlled trial

      Ji-Hye Park, Junga Lee, Minsuk Oh, Hyuna Park, Jisuk Chae, Dong-Il Kim, Mi Kyung Lee, Yong Jin Yoon, Chul Won Lee, Seho Park, Lee W. Jones, Nam Kyu Kim, Seung Il Kim and Justin Y. Jeon

      Article first published online: 12 MAY 2015 | DOI: 10.1002/cncr.29400

      An oncologist's exercise recommendation may not be enough to increase exercise participation among cancer survivors. Providing an exercise motivation package in addition to the oncologist's exercise recommendation to increase the level of exercise among survivors of breast and colorectal cancer should be considered.

    3. Outcomes Research
      Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort

      Carmen L. Wilson, Wei Liu, Jun J. Yang, Guolian Kang, Rohit P. Ojha, Geoffrey A. Neale, Deo Kumar Srivastava, James G. Gurney, Melissa M. Hudson, Leslie L. Robison and Kirsten K. Ness

      Article first published online: 11 MAY 2015 | DOI: 10.1002/cncr.29153

      Childhood cancer survivors are at high risk of obesity; however, the contribution of germline polymorphisms underlying obesity remains understudied. Genes involved in neural connectivity and clinical factors, including glucocorticoid exposure and abdominal radiation, can modify the odds of obesity in long-term survivors who previously received cranial radiation.

  7. Erratum

    1. You have free access to this content
  8. Original Articles

    1. Disease Site

      Head and Neck Disease
      The role of Epstein-Barr virus-encoded microRNA BART7 status of resection margins in the prediction of local recurrence after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma

      Jimmy Yu Wai Chan, Stanley Thian Sze Wong and William Ignace Wei

      Article first published online: 8 MAY 2015 | DOI: 10.1002/cncr.29380

      Tissue levels of the Epstein-Barr virus-encoded Bam HI-A rightward transcript 7 microRNA (BART7) are useful for identifying a subgroup of patients with histologically clear margins who are at increased risk of subsequent local recurrence of nasopharyngeal carcinoma. Postoperative adjuvant treatment is warranted for these patients.

  9. Communications

    1. You have free access to this content
      A Titan exits stage left: Summary of the Waun Ki Hong Festschrift

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29410

      On August 15, 2014, at The University of Texas MD Anderson Cancer Center in Houston, Dr. Fadlo Khuri, along with co-chairs Drs. James Abbruzzese, Patrick Hwu, Roy Herbst, and Scott Lippman, chaired a Festschrift celebrating the lifetime of accomplishments of Dr. Waun Ki Hong. A series of lectures celebrating Dr. Hong's legacy ensued, highlighting his accomplishments in the areas of induction chemotherapy, organ preservation, head and neck biology, carcinogenesis, and chemoprevention, as well as his leadership in the biological interrogation of biomarker-driven pathways in lung and head and neck cancer and his transformation of the culture of mentorship and multidisciplinary science at The University of Texas MD Anderson Cancer Center.

    2. You have free access to this content
      Honoring Dr. Waun Ki Hong, a cancer pioneer and visionary: On the occasion of his Festschrift, August 14, 2014

      Howard K. Koh

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29411

      At a special dinner, the keynote speaker, Dr. Howard H. Koh, the immediate past U.S. Assistant Secretary for Health gave a speech honoring Dr. Waun Ki Hong on the occasion of his Festschrift on August 14, 2014.

  10. Original Articles

    1. Disease Site

      Head and Neck Disease
      Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

      Edwin P. Hui, Brigette B. Y. Ma, K. C. Allen Chan, Charles M. L. Chan, Cesar S. C. Wong, Ka Fai To, Anthony W. H. Chan, Stewart Y. Tung, Wai-Tong Ng, Ashley C. Cheng, Victor H. F. Lee, Stephen L. Chan, Herbert H. F. Loong, Michael K. M. Kam, Sing-Fai Leung, Rosalie Ho, Frankie Mo, Roger K. C. Ngan and Anthony T. C. Chan

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29413

      In a prospective biomarker study of patients with nasopharyngeal cancer, plasma Epstein-Barr virus DNA is validated as the most significant prognostic biomarker for use in selecting high-risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup of patients (approximately 7%) with plasma Epstein-Barr virus DNA-negative nasopharyngeal cancer who have an excellent prognosis and can be spared the toxicities of further therapy.

    2. Discipline

      Disparities Research
      Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives

      Roshan Bastani, Beth A. Glenn, Annette E. Maxwell, Patricia A. Ganz, Cynthia M. Mojica, Susan Alber, Catherine M. Crespi and L. Cindy Chang

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29403

      First-degree relatives of colorectal cancer cases are at an elevated risk of developing the disease but remain underscreened. An ethnically targeted intervention has been found to successfully increase screening for colorectal cancer in this group.

  11. Editorial

    1. Editorial

      Individualizing treatment for patients with nasopharyngeal cancer

      Wendy Hara and Quynh-Thu Le

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29418

      In this issue, Dr. Hui and colleagues report the largest multi-institutional, prospective trial to date validating circulating Epstein-Barr virus DNA as a prognostic biomarker for patients with nasopharyngeal cancer after chemoradiotherapy. The ERCC1 C118T single nucleotide polymorphism genotype may also be a potential second biomarker for future investigation.

  12. Original Articles

    1. Discipline

      Translational Research
      Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

      Yusheng Lu, Haiyan Liang, Ting Yu, Jingjing Xie, Shuming Chen, Haiyan Dong, Patrick J. Sinko, Shu Lian, Jianguo Xu, Jichuang Wang, Suhong Yu, Jingwei Shao, Bo Yuan, Lie Wang and Lee Jia

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29444

      Circulating tumor cells not only might be used as real-time markers for predicting disease progression and survival for patients with metastatic and possibly even early-stage cancer but also might become a treatment target for the prevention of tumor metastasis. This article describes a novel method for the isolation and characterization of living circulating tumor cells. Isolated living circulating tumor cells are suitable for cell culture studies and will allow detailed molecular and eventually functional characterization, and this will determine the clinical value of circulating tumor cells for targeted and personalized medicine.

    2. Supportive Care
      Psychometric properties of an Australian supportive care needs assessment tool for Indigenous patients with cancer

      Gail Garvey, Vanessa L. Beesley, Monika Janda, Peter K. O'Rourke, Vincent Y.F. He, Anna L. Hawkes, Jacinta K. Elston, Adele C. Green, Joan Cunningham and Patricia C. Valery

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29433

      To date, insufficient attention has been given to the psychosocial needs of Indigenous patients with cancer. This newly developed and psychometrically tested tool is culturally relevant and sensitive to the needs of Indigenous Australians and can assist in addressing disparities with regard to support, information, services, and resource allocation.

  13. Commentary

    1. Business as usual is not acceptable

      K. Michael Cummings, James W. Gustafson Jr., David J. Sales, Fadlo R. Khuri and Graham W. Warren

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29442

      It is time for the cigarette industry to be held accountable for the consequences of manufacturing and promoting a product that causes so much disease and death. Punitive damage awards in tobacco litigation are an important way to make the cigarette companies recognize that Business as usual is not acceptable.

  14. Original Articles

    1. Disease Site

      Breast Disease
      5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

      Nina D. Wagner-Johnston, Jeff A. Sloan, Heshan Liu, Ann E. Kearns, Stephanie L. Hines, Suneetha Puttabasavaiah, Shaker R. Dakhil, Jacqueline M. Lafky, Edith A. Perez and Charles L. Loprinzi

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29327

      At 5 years of follow-up of this randomized controlled trial, immediate treatment with ZA prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer. Differences between the treatment arms with regard to the development of osteoporosis or fractures were not statistically significant.

    2. Hematologic Malignancies
      Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes

      Sameer A. Parikh, Jose F. Leis, Kari G. Chaffee, Timothy G. Call, Curtis A. Hanson, Wei Ding, Asher A. Chanan-Khan, Deborah Bowen, Michael Conte, Susan Schwager, Susan L. Slager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay and Tait D. Shanafelt

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29438

      This large, retrospective cohort study of approximately 1500 patients with chronic lymphocytic leukemia (CLL) indicates that approximately 25% of patients with CLL have hypogammaglobulinemia at the time of their initial diagnosis; and, among those who have normal serum immunoglobulin G levels at diagnosis, approximately 25% develop hypogammaglobulinemia over the next 10 years without the receipt of CLL therapy. Although the presence of hypogammaglobulinemia at initial diagnosis predicts the time to first CLL therapy, it does not have an impact on overall survival.

    3. Discipline

      Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study

      James D. Murphy, Grace L. Ma, Joel M. Baumgartner, Lisa Madlensky, Adam M. Burgoyne, Chih-Min Tang, Maria Elena Martinez and Jason K. Sicklick

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29434

      This is the first population-based study to characterize the associations and temporal relations between gastrointestinal stromal tumors and other cancers by both site and histological type. These results may carry important clinical implications for future cancer screening and treatment strategies.

  15. Editorials

    1. And the GIST is: When one has a GIST, think of an association!

      Constantine A. Stratakis

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29435

      Patients with gastrointestinal stromal tumors have been found to have other cancers more frequently than expected by chance in a population study. The findings are supportive of a genetic predisposition being more frequent in gastrointestinal stromal tumors, although other reasons cannot be excluded; clinicians need to bear in mind the possible association of a gastrointestinal stromal tumor with another primary cancer.

  16. Correspondence

  17. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Health care utilization and end-of-life care for older patients with acute myeloid leukemia

      Areej R. El-Jawahri, Gregory A. Abel, David P. Steensma, Thomas W. LeBlanc, Amir T. Fathi, Timothy A. Graubert, Daniel J. DeAngelo, Martha Wadleigh, Karen K. Ballen, Julia E. Foster, Eyal C. Attar, Philip C. Amrein, Andrew M. Brunner, Richard M. Stone and Jennifer S. Temel

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29430

      Older patients with acute myeloid leukemia spend a significant portion of their life after diagnosis in the hospital or clinic, and they are likely to die in the hospital. Despite their poor prognosis, older patients with acute myeloid leukemia infrequently receive palliative care or hospice services.

  18. Correspondence

    1. Age-related differences in quality of life among patients with diffuse large B-cell lymphoma

      Simone Oerlemans, Marten R. Nijziel and Lonneke V. van de Poll-Franse

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29427

  19. Editorials

    1. The graceful exit or reluctant demise of the older adult with acute myeloid leukemia

      Mikkael A. Sekeres and Aaron T. Gerds

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29428

      Older adults with acute myeloid leukemia should be better prepared for the difficult realities of their disease, and clinicians should adjust their optimism about the potential benefits of induction chemotherapy and practice under the assumption that patients will relapse or that therapy will fail. These patients and their families will then be ready for the health care burden they are about to endure and will be much more open to the suggestion of palliative approaches or hospice when the time comes, recognizing it as part of the natural course of events.

  20. Original Articles

    1. Discipline

      Outcomes Research
      Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice

      Amin Kay, Lingsong Yun, Nathan Taback and Monika K. Krzyzanowska

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29412

      Intermittent treatment strategies are being used in routine practice for patients with metastatic colorectal cancer. The frequency of breaks and the impact on survival and toxicity vary with the type of first-line chemotherapy.

    2. Disease Site

      Genitourinary Disease
      Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease

      Florence K. Keane, Ming-Hui Chen, Danjie Zhang, Brian J. Moran, Michelle H. Braccioforte and Anthony V. D'Amico

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29420

      Short-course neoadjuvant androgen deprivation therapy (ADT) does not reduce the risk of prostate cancer-specific mortality (PCSM) in men undergoing brachytherapy for favorable intermediate-risk prostate cancer and therefore should not be considered standard. It does appear to be superior in reducing PCSM risk when compared with neoadjuvant radiotherapy in men with unfavorable intermediate-risk prostate cancer, making short-course neoadjuvant ADT and brachytherapy a preferred treatment option in these men.

    3. Discipline

      Psychosocial Oncology
      Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors

      Moriah J. Brier, Dianne L. Chambless, Laura Lee and Jun J. Mao

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29407

      The results of this study demonstrate the psychometric validity of the Penn Arthralgia Aging Scale among breast cancer survivors on aromatase inhibitors. This scale captures women's perceptions of aging due to arthralgia and predicts incremental variance in depression, anxiety, and pain interference above and beyond joint pain severity.

    4. Disease Site

      Breast Disease
      Is mastectomy undertreatment for low-risk breast cancers eligible for breast-conserving therapy?

      Sanjay P. Bagaria, Nabil Wasif, Bhupendra Rawal, Sarah A. McLaughlin and Armando E. Giuliano

      Article first published online: 28 APR 2015 | DOI: 10.1002/cncr.29416

      Patients with estrogen receptor–positive, low-grade breast cancers appear to have a survival disadvantage when they are treated with mastectomy versus breast-conserving therapy. Biomarker profiles may help to optimize the choice of local therapy.

    5. Discipline

      Disparities Research
      Participants' barriers to diagnostic resolution and factors associated with needing patient navigation

      Jessica L. Krok-Schoen, Brittany M. Brewer, Gregory S. Young, Rory C. Weier, Cathy M. Tatum, Cecilia R. DeGraffinreid and Electra D. Paskett

      Article first published online: 28 APR 2015 | DOI: 10.1002/cncr.29414

      Multiple demographic and psychosocial factors are associated with barriers to diagnostic resolution. Facilities accredited by the American College of Surgeons Commission on Cancer need to have processes in place to identify patients most likely to have barriers to care and to assign them to patient navigation to ensure compliance with the Commission on Cancer mandate and provide timely care for all patients.

    6. Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer

      Stephen R. Grant, Gary V. Walker, B. Ashleigh Guadagnolo, Matthew Koshy, Pamela K. Allen and Usama Mahmood

      Article first published online: 27 APR 2015 | DOI: 10.1002/cncr.29120

      In the United States, an estimated 48 million individuals live without health insurance. The Surveillance, Epidemiology, and End Results (SEER) data set was used to demonstrate variability in insurance status by patient demographics and type of cancer diagnosis.

    7. Clinical Trials
      You have full text access to this OnlineOpen article
      A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

      Maria E. Cabanillas, Martin Schlumberger, Barbara Jarzab, Renato G. Martins, Furio Pacini, Bruce Robinson, Judith C. McCaffrey, Manisha H. Shah, Donald L. Bodenner, Duncan Topliss, Corina Andresen, James P. O'Brien, Min Ren, Yasuhiro Funahashi, Roger Allison, Rossella Elisei, Kate Newbold, Lisa F. Licitra, Steven I. Sherman and Douglas W. Ball

      Article first published online: 24 APR 2015 | DOI: 10.1002/cncr.29395

      This phase 2 study demonstrates that lenvatinib produces encouraging objective response and progression-free survival rates in patients with radioiodine-refractory, differentiated thyroid cancer and also has a well defined safety profile. Lenvatinib also exhibits activity in patients who previously received vascular endothelial growth factor/vascular endothelial growth factor receptor-targeted therapies.

    8. Disparities Research
      Paths to health equity: Local area variation in progress toward eliminating breast cancer mortality disparities, 1990-2009

      George Rust, Shun Zhang, Khusdeep Malhotra, Leroy Reese, Luceta McRoy, Peter Baltrus, Lee Caplan and Robert S. Levine

      Article first published online: 23 APR 2015 | DOI: 10.1002/cncr.29405

      Although most US counties show persistent or even widening racial disparities in breast cancer mortality, some counties have sustained both optimal and equitable outcomes for African American women for decades, and others have shown a path from cancer disparities to equality.

    9. Outcomes Research
      Patterns of change in cognitive function with anastrozole therapy

      Catherine M. Bender, John D. Merriman, Amanda L. Gentry, Gretchen M. Ahrendt, Sarah L. Berga, Adam M. Brufsky, Frances E. Casillo, Meredith M. Dailey, Kirk I. Erickson, Frances M. Kratofil, Priscilla F. McAuliffe, Margaret Q. Rosenzweig, Christopher M. Ryan and Susan M. Sereika

      Article first published online: 23 APR 2015 | DOI: 10.1002/cncr.29393

      In comparison with controls, women with breast cancer have poorer executive functioning from the period before therapy through the first 18 months of therapy. Declines in working memory and concentration with initial exposure to anastrozole have been observed.

    10. Disease Site

      Hepatobiliary Disease
      Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma

      Gaya Spolverato, Muhammad Y. Yakoob, Yuhree Kim, Sorin Alexandrescu, Hugo P. Marques, Jorge Lamelas, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Carlo Pulitano, Todd W. Bauer, Feng Shen, George A. Poultsides, J. Wallis Marsh and Timothy M. Pawlik

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29419

      Postoperative complications were found to be independent predictors of worse long-term outcomes among patients undergoing surgery for intrahepatic cholangiocarcinoma. The prevention and management of postoperative complications is crucial to increase both short-term and long-term survival.

    11. Breast Disease
      Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

      Sarah S. Mougalian, Pamela R. Soulos, Brigid K. Killelea, Donald R. Lannin, Maysa M. Abu-Khalaf, Michael P. DiGiovanna, Tara B. Sanft, Lajos Pusztai, Cary P. Gross and Anees B. Chagpar

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29348

      To the authors' knowledge, the patterns of use of neoadjuvant chemotherapy (NAC) for patients with breast cancer in national practice are unknown. Although the use of NAC has been increasing since 2003, substantial variation exists, and fewer than 50% of patients with stage III breast cancer receive NAC.

    12. Discipline

      Outcomes Research
      Physician's peer exposure and the adoption of a new cancer treatment modality

      Craig Evan Pollack, Pamela R. Soulos and Cary P. Gross

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29409

      New technologies frequently diffuse into clinical practice and increase the costs of cancer care. Studying brachytherapy for women with early-stage breast cancer, the authors report that surgeons who were exposed to early-adopting surgical peers were more likely to use brachytherapy over time.

    13. Clinical Trials
      Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

      Rana R. McKay, Kathryn P. Gray, Julia H. Hayes, Glenn J. Bubley, Jonathan E. Rosenberg, Arif Hussain, Philip W. Kantoff and Mary-Ellen Taplin

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29398

    14. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

      Bhumsuk Keam, Sung-Bae Kim, Seong Hoon Shin, Byoung Chul Cho, Keun-Wook Lee, Min Kyoung Kim, Hwan-Jung Yun, Se-Hoon Lee, Dok Hyun Yoon and Yung-Jue Bang

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29401

      Dovitinib shows promising antitumor activity in the treatment of adenoid cystic carcinoma.

  21. Commentary

    1. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country

      Mauricio Burotto and Vinay Prasad

      Article first published online: 22 APR 2015 | DOI: 10.1002/cncr.29408

      Although low- and middle-income countries face countless challenges that high-income countries do not, they still manage to make funding available for biomedical research and discovery. These nations must conduct research preferentially based on original work and avoid replicative research.

  22. Original Articles

    1. Discipline

      Supportive Care
      The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

      Laurien M. Buffart, Robert U. Newton, Mai J. Chinapaw, Dennis R. Taaffe, Nigel A. Spry, James W. Denham, David J. Joseph, David S. Lamb, Johannes Brug and Daniel A. Galvão

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29406

      The effects of aerobic and resistance exercise on cancer-specific health-related quality of life appear to be stronger for older survivors of prostate cancer who are married, started exercising sooner after their diagnosis, and previously used bisphosphonates. The effects of aerobic and resistance exercise on global quality of life, physical function, and social function appear to be mediated by lower body functional performance.

    2. Symptom Control and Palliative Care
      How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium

      Kelly M. Kenzik, Patricia A. Ganz, Michelle Y. Martin, Laura Petersen, Ron D. Hays, Neeraj Arora and Maria Pisu

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29415

      Symptom and health-related quality-of-life assessments are important to understand patient needs at diagnosis, regardless of disease stage. Supportive care strategies should be implemented early in the cancer care process and across all disease stages.

    3. Disease Site

      Chest and Lung Disease
      Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

      Adrian G. Sacher, Lisa W. Le, Anthea Lau, Craig C. Earle and Natasha B. Leighl

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29386

      Most patients with metastatic non-small cell lung cancer in the general population still do not receive systemic therapy.

  23. Erratum

    1. You have free access to this content
  24. Review Articles

    1. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

      Elias Jabbour, Susan O'Brien, Marina Konopleva and Hagop Kantarjian

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29383

      Risk-adapted strategies are transforming the treatment and prognosis of adult acute lymphoblastic leukemia. The role of monoclonal antibodies and cytotoxic T-cell therapies continues to be defined. Their incorporation into frontline adult acute lymphoblastic leukemia therapy may increase the cure rates to levels achieved in pediatric acute lymphoblastic leukemia and may reduce the need for prolonged intensive and maintenance chemotherapy.

  25. Editorial

    1. Darkness before dawn, but will the sun always rise?

      Sai-Hong Ignatius Ou

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29388

      The treatment of lung cancer has advanced since 2009, the end of the study period for Sacher et al's study. The use of genomic profiling for lung cancer and the use of targeted immunotherapy should be analyzed in the coming years with Sacher et al's study as a reference.

  26. Original Articles

    1. Discipline

      Outcomes Research
      Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: A nationwide population-based study

      Chia-Jen Liu, Yiing-Jenq Chou, Chung-Jen Teng, Chun-Chi Lin, Yu-Ting Lee, Yu-Wen Hu, Chiu-Mei Yeh, Tzeng-Ji Chen and Nicole Huang

      Article first published online: 17 APR 2015 | DOI: 10.1002/cncr.29356

      Patients with colorectal cancer who undergo definitive surgery performed by higher-volume providers appear to have better outcomes. Surgeon volume may play a more important role than hospital volume in these patients.

    2. Epidemiology
      Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40

      Mauro Tognon, Mario Luppi, Alfredo Corallini, Angelo Taronna, Patrizia Barozzi, John Charles Rotondo, Manola Comar, Maria Vittoria Casali, Massimo Bovenzi, Antonio D'Agostino, Fabrizio Vinante, Antonella Rigo, Isacco Ferrarini, Giuseppe Barbanti-Brodano, Fernanda Martini and Elisa Mazzoni

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29404

      Non-Hodgkin lymphoma, the most common cancer of the lymphatic system, is of unknown etiology. The data indicate a strong association between non-Hodgkin lymphoma and simian virus 40 and thus suggest the need for innovative therapeutic approaches for this hematologic malignancy.

    3. Outcomes Research
      Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis

      Anca Prica, Kelvin Chan and Matthew Cheung

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29372

      A rituximab-containing monotherapy induction strategy for low-burden, asymptomatic advanced-stage follicular lymphoma is the dominant strategy in comparison with a watch and wait approach: it maximizes both life expectancy and quality-adjusted life expectancy and is cost-saving.

    4. Disease Site

      Chest and Lung Disease
      Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

      Peter C. Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne and Geoffrey R. Oxnard

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29397

      Anecdotal experience suggests that some patients with nonsmall lung cancer who progress on erlotinib can have continued disease control without a change in treatment. In this analysis, investigators study 92 patients with nonsmall lung cancer who develop objective disease progression while receiving first-line erlotinib on 3 clinical trials and demonstrate the potential benefits of delaying a change in treatment for patients who have epidermal growth factor receptor-mutant lung cancer and favorable progression characteristics.

    5. Hematologic Malignancies
      Development and psychometric evaluation of the Quality of Patient-Centered Cancer Care measure with hematological cancer survivors

      Flora Tzelepis, Robert W. Sanson-Fisher, Alix E. Hall, Mariko L. Carey, Christine L. Paul and Tara Clinton-McHarg

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29384

      The Quality of Patient-Centered Cancer Care measure has been developed in accordance with the Institute of Medicine's recommendations and has acceptable face, content, and construct validity and internal consistency. The Quality of Patient-Centered Cancer Care measure can be used to comprehensively assess patient-centered cancer care.

    6. Discipline

      Supportive Care
      The role of second-hand smoke exposure on smoking cessation in non–tobacco-related cancers

      Lawson Eng, Xin Qiu, Jie Su, Dan Pringle, Chongya Niu, Mary Mahler, Rebecca Charow, Jodie Villeneuve, Oleksandr Halytskyy, Christine Lam, Kyoko Tiessen, M. Catherine Brown, Doris Howell, Meredith E. Giuliani, Jennifer M. Jones, Shabbir M. H. Alibhai, David P. Goldstein, Wei Xu, Peter Selby and Geoffrey Liu

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29340

      Exposure to second-hand smoke at home is a significant barrier to smoking cessation across all cancer types. Second-hand smoke should be a key consideration in the development of survivorship programs geared toward smoking cessation for patients with cancer.

    7. Disease Site

      Chest and Lung Disease
      You have full text access to this OnlineOpen article
      Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE)

      Patricia M. Livingston, Melinda J. Craike, Jo Salmon, Kerry S. Courneya, Cadeyrn J. Gaskin, Steve F. Fraser, Mohammadreza Mohebbi, Suzanne Broadbent, Mari Botti, Bridie Kent and the ENGAGE Uro-Oncology Clinicians' Group

      Article first published online: 15 APR 2015 | DOI: 10.1002/cncr.29385

      Compared with men in the control condition, those who receive a clinician referral and 12-week supervised exercise program undertake more than twice as much vigorous exercise at follow-up, have almost 4 times the odds of meeting exercise guidelines, and nearly 5 times the odds of avoiding complete inactivity. The exercise program also has a positive impact on mental health outcomes for men living with prostate cancer.

  27. Review Articles

    1. A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties

      Rajshekhar Chakraborty, Bipin N. Savani, Mark Litzow, Mohamad Mohty and Shahrukh Hashmi

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29382

      Recent data indicate that 354 million visits to complementary and alternative medicine (CAM) practitioners in 2007 cost Americans $33.9 billion in out-of-pocket costs for products and visit charges. CAM use is an understudied area of hematopoietic stem cell transplant survivorship and clinicians should convey the risks and benefits of individual CAM therapies to their patients.

  28. Original Articles

    1. Disease Site

      Chest and Lung Disease
      Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer

      Apar Kishor Ganti, Christina D. Williams, Ajeet Gajra and Michael J. Kelley

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29360

      Older patients with early-stage non-small cell lung cancer derive a similar magnitude of benefit from adjuvant chemotherapy as younger patients. Adjuvant chemotherapy should not be withheld based on patient age alone.

    2. Head and Neck Disease
      Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era

      Florence K. Keane, Yui-Hui Chen, Bridget A. Neville, Roy B. Tishler, Jonathan D. Schoenfeld, Paul J. Catalano and Danielle N. Margalit

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29402

      This population-based analysis demonstrates that the prognostic significance of tumor and nodal stages has changed significantly over time among patients with oropharyngeal cancer, and the current American Joint Committee on Cancer staging system does not consistently distinguish prognostic subgroups. These findings likely reflect the changing demographics of oropharyngeal squamous cell carcinoma and support current efforts to update the American Joint Committee on Cancer staging system for oropharyngeal cancer.

    3. Breast Disease
      Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

      Matthew D. Galsky, Sumanta K. Pal, Simon Chowdhury, Lauren C. Harshman, Simon J. Crabb, Yu-Ning Wong, Evan Y. Yu, Thomas Powles, Erin L. Moshier, Sylvain Ladoire, Syed A. Hussain, Neeraj Agarwal, Ulka N. Vaishampayan, Federica Recine, Dominik Berthold, Andrea Necchi, Christine Theodore, Matthew I. Milowsky, Joaquim Bellmunt, Jonathan E. Rosenberg and for the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29387

      The use of neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer is supported by randomized, phase 3 studies. The current analysis, which includes more than 200 patients, supports the use of cisplatin with gemcitabine as an alternative regimen to methotrexate, vinblastine, doxorubicin, and cisplatin.

    4. Neurology
      Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act

      Therese A. Dolecek, Emily Van Meter Dressler, Jigisha P. Thakkar, Meng Liu, Abeer Al-Qaisi and John L. Villano

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29379

      Meningioma incidence has increased since the implementation of Public Law 107-260, the Benign Brain Tumor Cancer Registries Act, which mandates the collection of nonmalignant brain tumors. Current treatments for meningioma are concerning for a significant percentage of patients who do not receive surgical or radiation treatments for higher grade meningiomas.

  29. Commentary

    1. A note from history: Landmarks in history of cancer, part 7

      Steven I. Hajdu, Manjunath Vadmal and Ping Tang

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29365

      Major events and discoveries in cancer research, prevention, diagnosis, and treatment that have taken place between 1970 and 1995 are reviewed. These 2 and a half decades are the high-water mark in clinical oncology: a period when oncology transformed from art to science.

  30. Original Articles

    1. Discipline

      Pediatric Oncology
      Practical communication guidance to improve phase 1 informed consent conversations and decision-making in pediatric oncology

      Liza-Marie Johnson, Angela C. Leek, Dennis Drotar, Robert B. Noll, Susan R. Rheingold, Eric D. Kodish and Justin N. Baker

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29354

      Despite informed consent conversations, parental understanding of the basic scientific concepts and general purpose of pediatric oncology trials remains suboptimal. The authors offer a communication model based on stakeholder suggestions to improve the quality of these conversations.

    2. Disease Site

      Breast Disease
      Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007

      Henry G. Kaplan, Judith A. Malmgren, Mary K. Atwood and Gregory S. Calip

      Article first published online: 14 APR 2015 | DOI: 10.1002/cncr.29371

      Better breast cancer survival over time is related to mammography detection, hormone therapy, and taxane-containing chemotherapy treatment. Treatment improvements alone are not sufficient to explain the observed survival improvements over time.

    3. Gynecologic Oncology
      NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer

      Akila N. Viswanathan, Jennifer Moughan, Brigitte E. Miller, Ying Xiao, Anuja Jhingran, Lorraine Portelance, Walter R. Bosch, Ursula A. Matulonis, Neil S. Horowitz, Robert S. Mannel, Luis Souhami, Beth A. Erickson, Kathryn A. Winter, William Small Jr and David K. Gaffney

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29337

      Postoperative bevacizumab added to chemotherapy and pelvic intensity-modulated radiotherapy is well tolerated. This combined modality therapeutic approach results in high overall survival rates at 2 years for patients with high-risk endometrial carcinoma.

  31. Review Articles

    1. The impact of neighborhood social and built environment factors across the cancer continuum: Current research, methodological considerations, and future directions

      Scarlett Lin Gomez, Salma Shariff-Marco, Mindy DeRouen, Theresa H. M. Keegan, Irene H. Yen, Mahasin Mujahid, William A. Satariano and Sally L. Glaser

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29345

      Neighborhood social and built environments have been recognized as important contexts in which health is shaped. The literature relating various cancer outcomes to neighborhood social and built environment factors is reviewed, and the authors discuss methodological considerations for this area of research.

  32. Original Article

    1. Disease Site

      Chest and Lung Disease
      Comparative effectiveness of surgery and radiosurgery for stage I non–small cell lung cancer

      James B. Yu, Pamela R. Soulos, Laura D. Cramer, Roy H. Decker, Anthony W. Kim and Cary P. Gross

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29359

  33. Original Articles

    1. Discipline

      Pediatric Oncology
      Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2

      James I. Geller, Peter F. Ehrlich, Nicholas G. Cost, Geetika Khanna, Elizabeth A. Mullen, Eric J. Gratias, Arlene Naranjo, Jeffrey S. Dome and Elizabeth J. Perlman

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29368

      Pediatric and adolescent renal cell carcinoma typically presents at an advanced stage with frequent involvement of the lymph nodes and with translocation morphology as the most common histology. The high rate of positive lymph nodes noted even with small associated primary tumors, poor imaging sensitivity for lymph node involvement, and frequent failure to sample lymph nodes presents an opportunity for improved diagnostics and care.

    2. Quality of Life
      Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy

      Claudio Jeldres, Jennifer Cullen, Lauren M. Hurwitz, Erika M. Wolff, Katherine E. Levie, Katherine Odem-Davis, Richard B. Johnston, Khanh N. Pham, Inger L. Rosner, Timothy C. Brand, James O. L'Esperance, Joseph R. Sterbis, Ruth Etzioni and Christopher R. Porter

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29370

      Patients who undergo surgery for low-risk prostate cancer experience worse urinary and sexual function yet have similar mental health outcomes compared with patients on active surveillance. These results support the use of active surveillance for low-risk patients who seek to maintain their quality of life after prostate cancer diagnosis.

    3. Disease Site

      Hematologic Malignancies
      Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group

      Thorsten Braun, Sophie Cereja, Sylvie Chevret, Emmanuel Raffoux, Marie Beaumont, Laurence Detourmignies, Arnaud Pigneux, Xavier Thomas, Dominique Bordessoule, Agnès Guerci, Thierry Lamy, Christian Recher, Xavier Poiré, Olivier Tournilhac, Olivier Spertini, Christine Chomienne, Laurent Degos, Hervé Dombret, Lionel Adès, Pierre Fenaux and the French-Belgian-Swiss APL Group

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29389

      The current results suggest that, at least for secondary acute promyelocytic leukemia (APL), evolving strategies in the treatment of cancers have modified the primary tumors and the drugs involved leukemogenesis, but without reducing their incidence. These findings also confirm prospectively that patients with secondary APL have characteristics and outcomes similar to those of patients with de novo APL.

    4. Hepatobiliary Disease
      Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis

      Nima Kokabi, Juan C. Camacho, Minzhi Xing, Bassel F. El-Rayes, James R. Spivey, Stuart J. Knechtle and Hyun S. Kim

      Article first published online: 6 APR 2015 | DOI: 10.1002/cncr.29275

      Glass-based yttrium 90 radioembolization therapy appears to be a safe and viable therapy in patients with infiltrative hepatocellular carcinoma and portal vein thrombosis.

  34. Editorial

    1. Seduced by technology?

      W. Robert Lee

      Article first published online: 2 APR 2015 | DOI: 10.1002/cncr.29358

      Patients with prostate cancer report no improvement in bowel, bladder, or sexual symptoms when they receive intensity-modulated radiation therapy instead of 3-dimensional conformal radiation therapy.

  35. Original Articles

    1. Discipline

      Clinical Trials
      Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial

      Deborah W. Bruner, Daniel Hunt, Jeff M. Michalski, Walter R. Bosch, James M. Galvin, Mahul Amin, Canhua Xiao, Jean-Paul Bahary, Malti Patel, Susan Chafe, George Rodrigues, Harold Lau, Marie Duclos, Madhava Baikadi, Snehal Deshmukh and Howard M. Sandler

      Article first published online: 2 APR 2015 | DOI: 10.1002/cncr.29362

      The authors analyze a preliminary comparison of patient-reported outcomes from Radiation Therapy Oncology Group trial 0126 between men receiving high-dose radiation therapy (RT) for prostate cancer with either 3-dimensional conformal RT (3D-CRT) or intensity-modulated RT (IMRT). Despite statistically significant reductions in the dose and volume to normal structures using IMRT, the results indicate no differences in clinically significant patient-reported outcomes for bowel, bladder, or sexual functions at similar doses delivered by IMRT compared with 3D-CRT.

  36. In Memoriam

    1. You have free access to this content
      Meir Wetzler, MD

      Razelle Kurzrock, Zeev Estrov, Moshe Talpaz and Hagop M. Kantarjian

      Article first published online: 1 APR 2015 | DOI: 10.1002/cncr.29391

  37. Original Articles

    1. Discipline

      Pediatric Oncology
      Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy

      Rodrigo B. Interiano, Noel Delos Santos, Sujuan Huang, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Daniel M. Green and Andrew M. Davidoff

      Article first published online: 1 APR 2015 | DOI: 10.1002/cncr.29373

      Partial nephrectomy is occasionally considered for patients with unilateral Wilms tumor to avoid the theoretical complication of renal insufficiency. In the current study, the authors evaluate the prevalence of hypertension and impaired renal function in long-term survivors of nonsyndromic unilateral Wilms tumor who were treated without nephrotoxic chemotherapy or ionizing radiation and report that <7% of patients had hypertension and <3% had significant renal dysfunction at a median follow-up of nearly 20 years after unilateral radical nephrectomy.

    2. Clinical Trials
      Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study

      Renata Pasqualini, Randall E. Millikan, Dawn R. Christianson, Marina Cardó-Vila, Wouter H. P. Driessen, Ricardo J. Giordano, Amin Hajitou, Anh G. Hoang, Sijin Wen, Kirstin F. Barnhart, Wallace B. Baze, Valerie D. Marcott, David H. Hawke, Kim-Anh Do, Nora M. Navone, Eleni Efstathiou, Patricia Troncoso, Roy R. Lobb, Christopher J. Logothetis and Wadih Arap

      Article first published online: 1 APR 2015 | DOI: 10.1002/cncr.29344

      The authors report on the development of a new ligand-directed peptidomimetic (termed bone metastasis-targeting peptidomimetic-11) for interleukin-11 receptor-based human vascular targeting, including the translation from preclinical studies to a first-in-class, first-in-man clinical trial in patients with metastatic, castrate-resistant prostate cancer.

  38. Editorial

    1. Addressing apoptosis to tumor zip codes

      Zachery R. Reichert and Maha HA. Hussain

      Article first published online: 1 APR 2015 | DOI: 10.1002/cncr.29346

      In the current issue of Cancer, Pasqualini and colleagues report on a study in which they target prostatic tumor vasculature signatures with an apoptosis-inducing, peptidomimetic drug. The authors of this editorial place this vascular-targeting discovery into a broader clinical context while focusing on opportunities and challenges in implementing it further.

  39. Retraction

    1. You have free access to this content
  40. Original Articles

    1. Discipline

      Disparities Research
      Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases

      Julie Hallet, Calvin H. L. Law, Paul J. Karanicolas, Refik Saskin, Ning Liu and Simron Singh

      Article first published online: 30 MAR 2015 | DOI: 10.1002/cncr.29338

      Neuroendocrine tumors are more commonly diagnosed and portend a worse prognosis in rural areas versus urban areas despite similar patterns of advanced stages at presentation. This may be related to a different biology (highlighted by increased distant recurrence in rural areas) and partly to geography and socioeconomic status variations that affect health care access and delivery.

    2. Translational Research
      Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer

      Hideaki Kinugasa, Kazuhiro Nouso, Koji Miyahara, Yuki Morimoto, Chihiro Dohi, Koichiro Tsutsumi, Hironari Kato, Takehiro Matsubara, Hiroyuki Okada and Kazuhide Yamamoto

      Article first published online: 30 MAR 2015 | DOI: 10.1002/cncr.29364

      In the current study, K-ras mutations were detected in cell-free serum circulating tumor DNA in 62.6% of patients with pancreatic cancer using digital polymerase chain reaction. The G12V mutation, which is one type of K-ras mutation in circulating tumor DNA, was associated with a poor prognosis.

    3. Clinical Trials
      Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

      Ramesh K. Ramanathan, Shannon L. McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina C. Baranda, Tara E. Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro and Charles D. Blanke

      Article first published online: 30 MAR 2015 | DOI: 10.1002/cncr.29363

      MK-2206 is well tolerated in patients with gastric/gastroesophageal junction cancers, and there is some evidence of activity, but overall survival (5.1 months) is less than anticipated (6.5 months).

    4. Disease Site

      Head and Neck Disease
      Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes

      Li Xu, Hongwei Tang, Diane W. Chen, Adel K. El-Naggar, Peng Wei and Erich M. Sturgis

      Article first published online: 30 MAR 2015 | DOI: 10.1002/cncr.29381

      Salivary gland carcinomas are a rare malignancy with unknown etiology. In the current study, the authors perform a genome-wide association analysis of salivary gland carcinomas and identify a panel of coding single-nucleotide polymorphisms associated with the risk of salivary gland carcinoma and its mucoepidermoid carcinoma subtype.

  41. Commentary

    1. You have free access to this content
      Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer

      Joan L. Walker, C. Bethan Powell, Lee-may Chen, Jeanne Carter, Victoria L. Bae Jump, Lynn P. Parker, Mark E. Borowsky and Randall K. Gibb

      Article first published online: 27 MAR 2015 | DOI: 10.1002/cncr.29321

      Death from ovarian cancer could theoretically be reduced with feasible interventions for all women and with the identification of high-risk women for genetic testing and risk-reducing salpingo-oophorectomy. Women and their physicians should consider oral contraceptives for prevention, opportunistic salpingectomy for sterilization at the completion of childbearing, and salpingectomy at the time of hysterectomy.

    2. You have free access to this content
      Ovarian cancer prevention: Time for primetime?

      Otis W. Brawley

      Article first published online: 27 MAR 2015 | DOI: 10.1002/cncr.29347

      In this issue of Cancer, members of the Society of Gynecologic Oncology review the etiology of ovarian cancer and present the society's recommendations for the prevention of the disease. They call for a concerted effort to identify women at high risk who are most likely to benefit from cancer chemotherapy or surgical prevention.

  42. Editorial

    1. You have free access to this content
      Time to divest from tobacco-funded research

      Fadlo R. Khuri and Suresh S. Ramalingam

      Article first published online: 26 MAR 2015 | DOI: 10.1002/cncr.29361

      In this editorial, the Editor-in-Chief and Section Editor for Chest and Lung Disease explain why Cancer will no longer consider any work that is funded directly or indirectly from tobacco companies or their subsidiaries.

  43. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

      Tapan M. Kadia, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Alessandra Ferrajoli, Marina Konopleva, Jan Burger, Xuelin Huang, Xuemei Wang, Sherry Pierce, Mark Brandt, Jennie Feliu, Jorge Cortes and Hagop Kantarjian

      Article first published online: 25 MAR 2015 | DOI: 10.1002/cncr.29367

      A prolonged, low-intensity regimen for older patients with acute myeloid leukemia provides high remission rates with low toxicity and long relapse-free survival.

    2. Genitourinary Disease
      Long-term impact of androgen-deprivation therapy on physical function and quality of life

      Shabbir M. H. Alibhai, Henriette Breunis, Narhari Timilshina, Gary Naglie, Ian Tannock, Murray Krahn, Padraig Warde, Neil E. Fleshner, Sarah Duff Canning and George Tomlinson

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29355

      In men with nonmetastatic prostate cancer, androgen-deprivation therapy is associated with declines in physical function (endurance, upper extremity strength, and lower extremity function) and quality of life over 1 year that persist or decline with 2 additional years of use.

    3. Discipline

      Clinical Trials
      Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

      Ruth Seggewiss-Bernhardt, Ralf C. Bargou, Yeow Tee Goh, A. Keith Stewart, Andrew Spencer, Adrian Alegre, Joan Bladé, Oliver G. Ottmann, Cristina Fernandez-Ibarra, Hong Lu, Scott Pain, Mikhail Akimov and Swaminathan Padmanabhan Iyer

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29339

      A promising cancer target in multiple myeloma is overexpressed heat shock protein 90, which is crucial in buffering the high levels of proteotoxic stress characteristic of this disease. This phase 1/1B trial shows disease stabilization with the small molecule heat shock protein 90 inhibitor NVP-AUY922 with or without bortezomib in patients with relapsed or refractory multiple myeloma. Increased therapeutic success should be reachable by mutual inhibition of survival feedback loops (eg, additional heat shock protein 70 inhibition).

    4. Disparities Research
      You have full text access to this OnlineOpen article
      Health system delay and its effect on clinical stage of breast cancer: Multicenter study

      Karla Unger-Saldaña, Alfonso Miranda, Gelasio Zarco-Espinosa, Fernando Mainero-Ratchelous, Enrique Bargalló-Rocha and Jesús Miguel Lázaro-León

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29331

      Both patient delays and provider delays are associated with higher probabilities of patients starting cancer treatment with advanced-stage disease. Research aimed at identifying specific access barriers to medical services is much needed to guide the design of tailored health policies, especially in developing countries.

    5. Disease Site

      Breast Disease
      The evolving role of adjuvant radiotherapy for elderly women with early-stage breast cancer

      Charles E. Rutter, Nataniel H. Lester-Coll, Brandon R. Mancini, Christopher D. Corso, Henry S. Park, Debra N. Yeboa, Cary P. Gross and Suzanne B. Evans

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29377

      The current study analyzes the ongoing national response to the Cancer and Leukemia Group B (CALGB) 9343 trial, including reduction in the use of radiotherapy (RT), adoption of hypofractionated RT, and the use of an RT boost to the lumpectomy cavity. Continued decreases in RT use and boost RT to the lumpectomy cavity after the presentation of mature trial data reflect the gradual integration of randomized evidence.

  44. Editorial

    1. What health care system delays reveal about inequalities in breast cancer medicine and global health

      Kristin Bright

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29333

      Health care system delays have an impact on clinical breast cancer stage and may be associated with disparities in outcomes. To evaluate the interaction of individual, organizational, and sociopolitical factors that affect system delays and to address the associated health disparities, understanding is needed regarding how providers, patients, and researchers conceptualize delays.

  45. Original Articles

    1. Discipline

      Dietary intake of fish, polyunsaturated fatty acids, and survival after breast cancer: A population-based follow-up study on Long Island, New York

      Nikhil K. Khankari, Patrick T. Bradshaw, Susan E. Steck, Ka He, Andrew F. Olshan, Jing Shen, Jiyoung Ahn, Yu Chen, Habibul Ahsan, Mary Beth Terry, Susan L. Teitelbaum, Alfred I. Neugut, Regina M. Santella and Marilie D. Gammon

      Article first published online: 24 MAR 2015 | DOI: 10.1002/cncr.29329

      All-cause mortality was reduced by 16% to 34% among women with breast cancer who reported a high intake of fish and long-chain ω-3 polyunsaturated fatty acids. Therefore, pending additional replication, long-chain ω-3 polyunsaturated fatty acid intake from fish and other dietary sources may provide a potential strategy for improving survival after a diagnosis of breast cancer.

    2. Disease Site

      Head and Neck Disease
      Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer

      Theresa Guo, Jesse R. Qualliotine, Patrick K. Ha, Joseph A. Califano, Young Kim, John R. Saunders, Ray G. Blanco, Gypsyamber D'Souza, Zhe Zhang, Christine H. Chung, Ana Kiess, Christine G. Gourin, Wayne Koch, Jeremy D. Richmon, Nishant Agrawal, David W. Eisele and Carole Fakhry

      Article first published online: 17 MAR 2015 | DOI: 10.1002/cncr.29323

      To the authors' knowledge, few clinical data currently are available regarding the clinical behavior and treatment of recurrent oropharyngeal cancer, particularly distant metastatic disease, within the context of human papillomavirus tumor status. In this retrospective analysis, surgical salvage is associated with prolonged overall survival for patients with recurrent locoregional and distant metastatic oropharyngeal cancer, independent of human papillomavirus tumor status.

    3. Discipline

      Medical Oncology
      Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas

      Helena A. Yu, Camelia S. Sima, Matthew D. Hellmann, Jarushka Naidoo, Natalie Busby, Katherine Rodriguez, Gregory J. Riely and Mark G. Kris

      Article first published online: 17 MAR 2015 | DOI: 10.1002/cncr.29313

      Stage of disease at the time of the initial diagnosis is associated with survival from the time of diagnosis of metastatic disease in specific molecular subsets of lung cancer. Stage at diagnosis should be accounted for in prospective studies among patients with metastatic lung cancer.

    4. Disparities Research
      Patient characteristics associated with the level of patient-reported care coordination among male patients with colorectal cancer in the Veterans Affairs healthcare system

      George L. Jackson, Leah L. Zullig, Sean M. Phelan, Dawn Provenzale, Joan M. Griffin, Steven B. Clauser, David A. Haggstrom, Rahul M. Jindal and Michelle van Ryn

      Article first published online: 17 MAR 2015 | DOI: 10.1002/cncr.29341

      The current study sought to determine whether patient characteristics, including race/ethnicity, were associated with patient-reported care coordination among patients with colorectal cancer who were treated in the Veterans Affairs health care system. Patients with CRC who are treated in the Veterans Affairs system report high levels of care coordination, and there appears to be no racial/ethnic disparity in reported coordination.

    5. Epidemiology
      Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda

      Dominique Sighoko, Temidayo Ogundiran, Adeyinka Ademola, Clement Adebamowo, Lin Chen, Stella Odedina, Imaria Anetor, Paul Ndom, Antony Gakwaya, Oladosu Ojengbede, Dezheng Huo and Olufunmilayo I. Olopade

      Article first published online: 17 MAR 2015 | DOI: 10.1002/cncr.29305

      There is no transient increase in breast cancer risk after a full-term pregnancy among African women. The protection conferred by pregnancy occurs immediately after the first full-term pregnancy regardless of the age at that pregnancy and the number of pregnancies.

    6. Disease Site

      Head and Neck Disease
      Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma

      Masamichi Hayashi, Gaosong Wu, Jong-Lyel Roh, Xiaofei Chang, Xiufeng Li, Julie Ahn, Marla Goldsmith, Zubair Khan, Justin Bishop, Zhe Zhang, Xian Chong Zhou, Jeremy Richmon, Nishant Agrawal and Wayne M. Koch

      Article first published online: 13 MAR 2015 | DOI: 10.1002/cncr.29303

      The results from this study reveal that combinations of 2 methylated genes in histologically negative, deep surgical margins are significantly associated with a poor prognosis in a cohort of prospectively collected patients with head and neck squamous cell carcinoma (n = 73). Among 41 patients who have tumors with methylation of both EDNRB and HOXA9, no locoregional recurrences are observed within 2 years when margins are negative for these markers.


  1. 1 - 100
  2. 101 - 136